Lilly bets on prevention with three biotech acquisitions

Lilly announced agreements to acquire Curevo, LimmaTech Biologics and Vaccine Company to broaden its infectious-disease portfolio with vaccine-based prevention for shingles, bacterial pathogens and EBV-related disease, respectively. The deals could total up to $3.83 billion in potential cash payments, contingent on milestones and regulatory clearances, and closing is subject to customary conditions, reflecting Lilly's strategy to prevent disease at the source and address antimicrobial resistance.